Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - VANGUARD HEALTH SYSTEMS INC | c23895exv99w1.htm |
EX-99.2 - EXHIBIT 99.2 - VANGUARD HEALTH SYSTEMS INC | c23895exv99w2.htm |
EX-99.3 - EXHIBIT 99.3 - VANGUARD HEALTH SYSTEMS INC | c23895exv99w3.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 31, 2011 (October 31, 2011)
VANGUARD HEALTH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 001-35204 | 62-1698183 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
20 Burton Hills Boulevard, Suite 100, Nashville, Tennessee |
37215 |
|
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (615) 665-6000
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
The information contained in this Form 8-K (including the Exhibits
attached hereto) shall be deemed furnished and not be deemed filed
for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the liabilities of
that section. The information contained in this Form 8-K and the Exhibits
attached hereto may only be incorporated by reference in another filing
under the Exchange Act or under the Securities Act of 1933, as amended,
if such subsequent filing specifically references and incorporates the
information in this Form 8-K or the Exhibits attached hereto.
Item 2.02 Results of Operations and Financial Condition.
On October 31, 2011, Vanguard Health Systems, Inc. (the Company) issued a press release
announcing its operating results for the first quarter of its 2012 fiscal year. For information
regarding the operating results, the Company hereby incorporates by reference herein the
information set forth in its press release dated October 31, 2011, a copy of which is attached
hereto as Exhibit 99.1 (the Earnings Release).
The Earnings Release contains a non-GAAP financial measure, Adjusted EBITDA. For purposes of
Regulation G, a non-GAAP financial measure is a numerical measure of a registrants historical or
future financial performance, financial position or cash flows that excludes amounts, or is subject
to adjustments that have the effect of excluding amounts, that are included in the most directly
comparable measure calculated and presented in accordance with GAAP in the statement of operations,
balance sheet or statement of cash flows of the registrant; or includes amounts, or is subject to
adjustments that have the effect of including amounts, that are excluded from the most directly
comparable measure so calculated and presented. In this regard, GAAP refers to generally accepted
accounting principles in the United States. Pursuant to the requirements of Regulation G, the
Company has provided a reconciliation in the Earnings Release of Adjusted EBITDA to the most
directly comparable GAAP financial measure to Adjusted EBITDA, net income (loss) attributable to
Vanguard Health Systems, Inc. stockholders.
The Company defines Adjusted EBITDA as income (loss) before interest expense (net of interest
income), income taxes, depreciation and amortization, non-controlling interests, gain or loss on
the disposal of assets, equity method income, stock compensation, monitoring fees and expenses,
realized gains or losses on investments, acquisition related expenses, debt extinguishment costs,
impairment and restructuring charges, pension expense (credits) and discontinued operations, net of
taxes. Monitoring fees and expenses represent fees and reimbursed expenses paid to affiliates of
The Blackstone Group and Metalmark Subadvisor LLC for advisory and oversight services. It is
reasonable to expect these reconciling items to occur in future periods, but for many of them the
amounts recognized can vary significantly from period to period, do not relate directly to the
ongoing operations of the Companys healthcare facilities and complicate period to period
comparisons of our results of operations. Adjusted EBITDA should not be considered as a substitute
for net income (loss) attributable
to Vanguard Health Systems, Inc. stockholders, operating cash flows or other cash flow statement
data determined in accordance with GAAP. Additionally, Adjusted EBITDA is not intended to be a
measure of free cash flow available for managements discretionary use, since it does not consider
certain cash requirements such as interest payments, tax payments and other debt service
requirements. Because Adjusted EBITDA is not a GAAP measure and is susceptible to varying
calculations, Adjusted EBITDA, as presented by the Company, may not be comparable to similarly
titled measures of other companies.
Further, as additional supplementary financial disclosures covered by Regulation G, the
Company is hereby providing (1) an EBITDA-related, non-GAAP financial measure, the Adjusted EBITDA
Margin, for certain completed accounting periods and (2) a calculation of certain of the financial
covenants under the Companys senior secured credit agreement, for the twelve months ended
September 30, 2011, as well as presenting the reconciliations required by Regulation G
(collectively, the Supplementary Financial Information). The Supplementary Financial Information
is attached hereto as Exhibits 99.2 and 99.3 and is incorporated by reference herein.
Adjusted EBITDA is a measure used by management to evaluate its operating performance.
Management believes that Adjusted EBITDA and the Supplementary Financial Information provide
useful information about the Companys financial performance on the same basis as that viewed by
management to investors, lenders, financial analysts and rating agencies. These groups have
historically used EBITDA-related measures in the healthcare industry, along with other measures,
to estimate the value of a company, to make informed investment decisions, to evaluate a
companys operating performance compared to that of other companies in the healthcare industry
and to evaluate a companys leverage capacity and its ability to meet its debt service. Adjusted
EBITDA eliminates the uneven effect of non-cash depreciation of tangible assets and amortization
of intangible assets, much of which results from acquisitions accounted for under the purchase
method of accounting. Adjusted EBITDA also eliminates the effects of changes in interest rates,
which management believes relate to general trends in global capital markets, but are not
necessarily indicative of a companys operating performance.
A limitation of Adjusted EBITDA, however, is that it does not reflect the periodic cost of certain
capitalized assets that the Company uses to generate its revenues. The Company evaluates these
costs through other financial measures such as capital expenditures. Adjusted EBITDA also excludes
net interest expense, which is a significant expense because of the Companys substantial
indebtedness. Many of the items excluded from Adjusted EBITDA result from decisions outside the
control of operating management and may differ significantly from company to company due to
differing long-term decisions regarding capital structure, capital investment strategies, the tax
jurisdictions in which the companies operate and unique circumstances of acquired entities.
Adjusted EBITDA is also used by the Companys management to measure individual performance for
incentive compensation purposes and as an analytical indicator for purposes of allocating resources
to its operating businesses and assessing their performance, both internally and relative to the
Companys peers, as well as to evaluate the performance of the Companys healthcare facilities and
their regional and local management teams.
Item 7.01 Regulation FD Disclosure.
The press release referred to in Item 2.02 above includes the Companys initial earnings
guidance for its fiscal year ending June 30, 2012. Pursuant to
the requirements of Regulation G, the Company has provided
reconciliations in the Earnings Release for its projected Adjusted
EBITDA outlook and its projected diluted earnings per share outlook. A copy of the press release making this
announcement is attached as Exhibit 99.1 to this Form 8-K and is incorporated by reference into
this Item 7.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The exhibits filed as part of this Form 8-K are listed in the Exhibit
Index that is located at the end of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: October 31, 2011 | VANGUARD HEALTH SYSTEMS, INC. | |||
(Registrant) | ||||
BY: | /s/ James H. Spalding
|
|||
Executive Vice President, General Counsel & Secretary |
VANGUARD HEALTH SYSTEMS, INC.
EXHIBIT INDEX
EXHIBIT INDEX
Exhibit No. | Description | |||
99.1 | Press Release of Vanguard Health Systems, Inc., dated October
31, 2011, announcing first quarter fiscal 2012 operating
results and outlook for fiscal year 2012 |
|||
99.2 | Adjusted EBITDA Margin |
|||
99.3 | Calculation of Certain Financial Covenants under Senior
Secured Credit Agreement |